LONDON, UK: Beximco Pharmaceuticals Limited announced the launch of the world’s first generic molnupiravir, an oral antiviral drug for symptomatic COVID-19 recently developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics. The announcement comes following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh. Beximco Pharma’s branded…
Tag: Beximco Pharmaceuticals
Beximco completes £39.35 million acquisition of Sanofi Bangladesh
LONDON, UK: Beximco Pharmaceuticals Limited has now completed its acquisition of the majority stake in Sanofi Bangladesh Limited, first announced on 21 January 2021. The final consideration, payable in cash (post the closing adjustments previously outlined), was approximately £39.35 million. Sanofi Bangladesh has been present in Bangladesh since 1958. Beximco Pharma Managing Director, Mr Nazmul…